So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

Includes reviews of Elm Chevrolet from DealerRater. Want to share your experience with this dealership? My only issue was that they shorted me what my trade in cars value actually was by almost ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

Looking for the best biotech penny stocks? The most important innovation of the 1990s was the internet — today, it would be a vaccine for COVID-19. If these times have anything to say about it ...

I have been a loyal customer of West Elm, purchasing nearly all my furniture from them due to their appealing designs. However, I have found their products to lack durability. My most recent ...

Join biotech commentators Daphne Zohar, Josh Schimmer, and Brad Loncar for a weekly discussion of all things biotech. From emerging trends and investment opportunities to the challenges facing the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging field of treatments that can reprogramme immune cells inside patients ...

Nature Biotechnology is a monthly journal covering the science and business of biotechnology. It publishes new concepts in technology/methodology of relevance to the biological, biomedical ...

This fund holds a portfolio of 75-125 biotechnology stocks, balanced between established large-cap names and smaller companies with more growth potential but also more risk. The managers aim to ...